Toxicology – Beryllium

Core concept

Beryllium is a lightweight metal whose toxicity is primarily an occupational inhalational disease.

The two major pulmonary syndromes are:

High-level acute exposure → chemical pneumonitis

Chronic exposure/sensitization → chronic beryllium disease (CBD), a granulomatous interstitial lung disease

The key chronic mechanism is:

Beryllium exposure → beryllium sensitization → activation of beryllium-specific T lymphocytes → noncaseating granulomatous inflammation

CBD can closely mimic sarcoidosis.

Forms and Uses

Beryllium is used in:

• Aerospace
• Nuclear industries
• Electronics
• Missile and defense components
• Tool and die manufacturing
• Beryllium-copper alloys
• Dental laboratories
• Metal machining
• Atomic-energy research
• Specialty ceramics

The principal route of occupational toxicity is inhalation of beryllium-containing dusts and fumes.

Exposure may involve:

• Beryllium metal
• Beryllium oxide
• Beryllium salts
• Beryllium-containing alloys

Skin contamination and embedded particles may also cause sensitization and granulomatous reactions.

Toxicity

The severity of acute toxicity depends on:

• Airborne concentration
• Duration of exposure
• Solubility of the compound

NIOSH IDLH

The current NIOSH Immediately Dangerous to Life or Health (IDLH) concentration for beryllium compounds is:

4 mg/m³.

This should not be confused with acceptable occupational exposure limits, which are much lower.

Current Occupational Exposure Limits

Current OSHA limits are:

• 8-hour TWA PEL: 0.2 μg/m³
• 15-minute STEL: 2.0 μg/m³
• OSHA action level: 0.1 μg/m³ as an 8-hour TWA

These values are far lower than older historical workplace limits because low-level occupational exposure can cause sensitization, CBD, and contribute to lung-cancer risk.

Pathophysiology

Acute Beryllium Disease

High-level inhalational exposure produces direct inflammatory injury to the respiratory tract:

Beryllium inhalation → airway inflammation → tracheobronchitis/bronchiolitis → chemical pneumonitis ± pulmonary edema

Acute beryllium disease is now uncommon in workplaces with modern exposure controls.

Chronic Beryllium Disease

CBD is primarily a cell-mediated immune hypersensitivity disorder.

Beryllium-specific T cells accumulate in the lungs and thoracic lymph nodes, resulting in:

Chronic inflammation → noncaseating granulomas → progressive interstitial lung disease ± fibrosis

Disease may develop years or even decades after exposure has ended.

Beryllium Sensitization

Beryllium sensitization (BeS) means that the immune system has developed a specific cellular response to beryllium.

Patients with BeS may:

• Be completely asymptomatic
• Have normal chest imaging
• Have normal pulmonary function tests

BeS is identified primarily by the beryllium lymphocyte proliferation test (BeLPT).

Sensitization does not automatically mean the patient has chronic beryllium disease.

Clinical Features

Acute Beryllium Toxicity

HEENT / Upper Airway

High-concentration exposure may cause:

• Conjunctivitis
• Nasal irritation
• Epistaxis
• Facial discomfort
• Nasopharyngitis
• Pharyngeal inflammation

Severe historical exposures have caused:

• Ulceration
• Fissuring
• Nasal tissue injury

Pulmonary

Symptoms may include:

• Dry cough
• Chest pain
• Dyspnea
• Wheezing
• Rhonchi
• Tracheobronchitis
• Chemical pneumonitis
• Pulmonary edema
• Hypoxemia

Severe cases can progress to respiratory failure.

Chronic Beryllium Disease

Respiratory

Typical manifestations include:

• Progressive exertional dyspnea
• Chronic dry cough
• Reduced exercise tolerance
• Chest discomfort

Constitutional

Possible findings include:

• Fatigue
• Weight loss
• Fever
• Myalgias

Physical Findings

As disease progresses:

• Bibasilar crackles
• Wheezing
• Cyanosis
• Digital clubbing
• Hilar or mediastinal lymphadenopathy

ATSDR notes that early disease may be subtle or even asymptomatic.

Advanced Disease

Progressive CBD may result in:

• Pulmonary fibrosis
• Chronic hypoxemia
• Pulmonary hypertension
• Cor pulmonale
• Right-sided heart failure
• Respiratory failure

Dermatologic Effects

Beryllium can cause:

• Contact dermatitis
• Skin ulceration
• Impaired wound healing
• Subcutaneous granulomas

Embedded particles may produce persistent noncaseating granulomas at the site of injury and may contribute to sensitization.

Diagnosis

The older diagnostic checklist based on “four of six criteria” has largely been replaced by a more immunologically based approach.

Modern diagnosis emphasizes:

Evidence of beryllium sensitization + evidence of beryllium-related pulmonary disease

Current diagnostic criteria for CBD require evidence of both BeS and disease characterized by pulmonary inflammation/granuloma formation.

Occupational History

A detailed exposure history is essential.

Ask about:

• Aerospace work
• Nuclear facilities
• Electronics
• Metal machining
• Dental laboratories
• Beryllium-copper alloy production
• Defense industries
• Abrasive blasting
• Past employment many years earlier

Even apparently minor exposure can be clinically relevant.

Beryllium Lymphocyte Proliferation Test

The BeLPT is the principal test used to identify beryllium sensitization.

It measures proliferation of the patient’s lymphocytes when exposed to beryllium salts in vitro.

It can be performed using:

• Peripheral blood lymphocytes
• Bronchoalveolar lavage lymphocytes

Abnormal blood BeLPT results are generally confirmed with repeat testing because test variability can occur.

Bronchoscopy

Patients with suspected CBD may undergo:

Bronchoalveolar Lavage

BAL may show:

• Lymphocytic inflammation
• Positive BAL BeLPT

Transbronchial Lung Biopsy

Typical pathology includes:

• Noncaseating granulomas
• Mononuclear interstitial inflammation
• Variable pulmonary fibrosis

These findings closely resemble sarcoidosis.

Imaging

Chest X-ray

May be:

• Normal in early disease
• Diffusely interstitial
• Nodular
• Associated with hilar adenopathy

High-Resolution CT

HRCT is more sensitive than plain radiography and may demonstrate:

• Interstitial abnormalities
• Pulmonary nodules
• Fibrosis
• Hilar or mediastinal lymphadenopathy

A normal radiograph does not exclude early CBD.

Pulmonary Function Tests

Pulmonary function testing may be:

• Normal early
• Obstructive
• Restrictive
• Mixed

A reduction in DLCO may occur as pulmonary involvement progresses.

Exercise testing may reveal abnormalities before severe resting impairment becomes apparent.

Differential Diagnosis

The most important differential diagnosis is:

Sarcoidosis

Other possibilities include:

• Tuberculosis
• Silicosis
• Hypersensitivity pneumonitis
• Asbestosis
• Fungal infection
• Other interstitial lung diseases
• Pulmonary malignancy

Because sarcoidosis and CBD may be nearly indistinguishable clinically and histologically, occupational history and BeLPT testing are crucial.

Treatment

Acute Exposure

1. Remove from Exposure

Immediately move the patient away from the beryllium-containing environment.

2. Airway and Breathing

Provide:

• Supplemental oxygen when hypoxemic
• Bronchodilators for bronchospasm
• Ventilatory support if respiratory failure develops

Significant pneumonitis or hypoxemia warrants hospital management.

3. Skin Exposure

• Remove contaminated clothing
• Wash exposed skin thoroughly
• Irrigate contaminated wounds

Embedded particles may require specialist evaluation and removal.

Antidote

There is no specific antidote for beryllium toxicity.

Treatment is based on:

• Removal from exposure
• Respiratory support
• Management of inflammation
• Long-term monitoring for sensitization and CBD

Chronic Beryllium Disease

Remove Further Exposure

Further beryllium exposure should be minimized or eliminated whenever possible.

This is important even in sensitized individuals without established CBD.

Beryllium Sensitization Alone

Patients with BeS without clinically significant CBD generally do not require corticosteroids.

They require ongoing surveillance for development or progression of pulmonary disease.

Corticosteroids

Systemic corticosteroids are the principal therapy for symptomatic or progressive chronic beryllium disease.

Treatment is generally considered when there is:

• Significant dyspnea
• Severe cough
• Declining pulmonary function
• Deteriorating gas exchange
• Pulmonary hypertension
• Cor pulmonale

Prednisone is commonly used and tapered to the lowest dose that controls disease activity.

Treatment may need to continue for prolonged periods because disease activity can recur when corticosteroids are reduced.

Steroid-Sparing Therapy

In selected patients requiring prolonged treatment, specialist-directed therapies such as:

• Methotrexate
• Azathioprine

may be considered to reduce long-term corticosteroid exposure.

Supportive Treatment

Depending on severity:

• Supplemental oxygen
• Bronchodilators
• Pulmonary rehabilitation
• Influenza vaccination
• Pneumococcal vaccination
• Treatment of respiratory infections
• Management of pulmonary hypertension/right-heart failure

Monitoring

Patients with CBD should be followed with serial:

• Clinical assessment
• Pulmonary function tests
• DLCO
• Oxygenation assessment
• Exercise testing
• Chest imaging when indicated

Patients with isolated beryllium sensitization also require periodic monitoring because some subsequently develop CBD.

Carcinogenicity

Occupational beryllium exposure is associated with lung cancer risk, in addition to sensitization and chronic beryllium disease. OSHA specifically cites CBD and lung cancer among the major health risks addressed by its current exposure standard.

Prognosis

Acute Disease

Acute chemical pneumonitis may improve after exposure ends, although severe injury can produce prolonged respiratory impairment.

Chronic Disease

CBD has a variable course.

Some patients remain stable for long periods, whereas others develop progressive:

• Granulomatous inflammation
• Pulmonary fibrosis
• Hypoxemia
• Pulmonary hypertension
• Cor pulmonale
• Respiratory failure

There is no definitive cure for established CBD, although treatment can improve symptoms and stabilize disease.

Important Pitfalls

1. Misdiagnosing CBD as sarcoidosis

CBD may look almost identical to sarcoidosis clinically, radiologically, and histologically.

Always obtain a detailed occupational history.

2. Assuming a normal chest X-ray excludes disease

Early CBD may have a normal chest radiograph.

3. Confusing sensitization with disease

A positive BeLPT indicates beryllium sensitization, but does not alone establish clinically significant CBD.

4. Using the older diagnostic checklist

Modern diagnosis emphasizes:

BeLPT evidence of sensitization + evidence of pulmonary granulomatous disease

rather than the historical four-of-six diagnostic criteria.

5. Ignoring apparently minor exposure

Even relatively low or remote exposure may be important.

6. Missing skin exposure

Embedded particles can cause:

• Granulomas
• Ulceration
• Poor wound healing
• Sensitization

7. Using outdated workplace limits

Current OSHA limits are:

0.2 μg/m³ over 8 hours

and

2.0 μg/m³ over 15 minutes.

High-Yield Toxicology Pearls

Beryllium = occupational exposure + granulomatous lung disease

Think:

Beryllium exposure + progressive dyspnea + noncaseating granulomas → consider chronic beryllium disease

Key points:

• Main route: inhalation
• Acute high-level exposure → chemical pneumonitis
• Chronic toxicity is primarily immune-mediated
• Main target organs: lungs and thoracic lymph nodes
• Beryllium sensitization is detected by BeLPT
• CBD requires evidence of sensitization plus pulmonary disease
• Histology shows noncaseating granulomas
• CBD strongly resembles sarcoidosis
• Chest X-ray may be normal early
• PFTs may show obstructive, restrictive, or mixed disease
• DLCO may be reduced
• No specific antidote
• Symptomatic/progressive CBD is treated primarily with systemic corticosteroids
• Sensitization without active disease generally requires surveillance rather than steroids
• Current OSHA TWA PEL: 0.2 μg/m³
• Current OSHA STEL: 2.0 μg/m³
• NIOSH IDLH: 4 mg/m³
• Beryllium exposure is also associated with lung cancer risk

Toxicology – Benzoyl Peroxide

Core concept

Benzoyl peroxide is a topical oxidizing and keratolytic agent used primarily for acne.

Most clinical toxicity is local rather than systemic:

Skin exposure → irritation/contact dermatitis

Eye exposure → conjunctival/corneal irritation

Inhalation of concentrated powder → respiratory irritation

Serious systemic poisoning from ordinary topical acne preparations is uncommon.

Forms and Uses

Benzoyl peroxide is found in:

• Gels
• Creams
• Lotions
• Cleansers
• Washes
• Other topical acne products

Common acne formulations range from approximately 2.5–10%.

Benzoyl peroxide acts by:

• Releasing reactive oxygen species
• Reducing Cutibacterium acnes
• Producing keratolytic effects
• Promoting desquamation
• Reducing follicular obstruction

The FDA considers benzoyl peroxide an acceptable active ingredient in OTC topical acne products when appropriately labeled. (U.S. Food and Drug Administration)

Toxicity

There is no well-defined toxic oral dose for ordinary topical preparations.

Most accidental small ingestions cause:

• Oral irritation
• Nausea
• Vomiting
• Gastrointestinal discomfort

Systemic toxicity is uncommon.

Industrial concentrated benzoyl peroxide requires greater caution because it is an organic peroxide and combustible/reactive solid.

Occupational Exposure

Current NIOSH information lists:

• NIOSH REL: 5 mg/m³ TWA
• OSHA PEL: 5 mg/m³ TWA
• NIOSH IDLH: 1,500 mg/m³

The older source’s IDLH value of 1,000 mg/m³ is outdated. (CDC)

Important Physical Hazard

Concentrated benzoyl peroxide is not just an irritant.

It is:

• Combustible
• Strongly reactive
• Sensitive to heat
• Potentially sensitive to shock and friction
• Capable of explosive decomposition under hazardous industrial conditions

NIOSH notes that containers may explode when heated and that concentrated benzoyl peroxide is incompatible with multiple reactive substances. (CDC)

Clinical Features

Dermatologic

The most common adverse effects are:

• Erythema
• Dryness
• Burning
• Stinging
• Pruritus
• Peeling
• Mild edema

These effects are often greatest when treatment is first started.

Both:

• Irritant contact dermatitis
• Allergic contact dermatitis

may occur.

FDA labeling specifically warns about redness, burning, itching, peeling, and swelling. (U.S. Food and Drug Administration)

Severe Hypersensitivity

Rare but potentially serious hypersensitivity reactions have been reported with OTC acne products containing benzoyl peroxide.

Possible manifestations include:

• Urticaria
• Facial edema
• Lip or tongue swelling
• Throat tightness
• Dyspnea
• Syncope
• Anaphylaxis

FDA has reported rare serious hypersensitivity reactions associated with topical acne products, although in some reports it could not determine whether benzoyl peroxide itself, another ingredient, or a combination was responsible. (U.S. Food and Drug Administration)

Airway swelling, respiratory difficulty, or cardiovascular symptoms require emergency treatment as possible anaphylaxis.

Eye Exposure

Ocular exposure may cause:

• Burning
• Lacrimation
• Conjunctival irritation
• Conjunctivitis
• Corneal epithelial injury

Persistent:

• Pain
• Redness
• Photophobia
• Visual disturbance

warrants ophthalmologic evaluation.

Inhalation

Inhalation of powder or concentrated aerosol may cause:

• Nose irritation
• Throat irritation
• Cough
• Eye irritation
• Bronchial irritation

Significant inhalational exposure requires assessment for persistent respiratory symptoms.

Oral Exposure

Small accidental ingestion of topical preparations generally causes mild effects.

Possible symptoms include:

• Oral irritation
• Nausea
• Vomiting
• Abdominal discomfort

Severe systemic toxicity is not typical.

Diagnosis

Diagnosis is generally based on:

Exposure history + local clinical findings

No specific laboratory tests are usually needed for:

• Minor skin exposure
• Minor accidental ingestion
• Mild transient irritation

Investigations

Further evaluation may be appropriate when there is:

• Persistent respiratory distress
• Severe hypersensitivity
• Significant industrial exposure
• Uncertain coexposure
• Eye injury

For significant eye symptoms:

• Visual acuity
• Ocular examination
• Fluorescein examination when appropriate

Treatment

Skin Exposure

• Remove contaminated clothing if relevant
• Wash affected skin thoroughly with soap and water
• Stop benzoyl peroxide use if significant irritation develops

For mild irritation:

• Cool compresses
• Bland emollients
• Reduction or discontinuation of topical therapy

Severe dermatitis may require clinician-directed topical treatment.

Eye Exposure

Immediately irrigate with:

• Water
• Normal saline

Continue copious irrigation for at least approximately 15 minutes and remove contact lenses when easily possible.

Persistent pain, redness, corneal symptoms, or visual changes require medical/ophthalmologic evaluation.

Inhalation

• Remove the patient to fresh air
• Assess airway and breathing
• Give supplemental oxygen if clinically indicated
• Treat bronchospasm if present

Persistent respiratory symptoms warrant medical evaluation.

Ingestion

For an uncomplicated small accidental ingestion:

• Rinse the mouth
• Give a small amount of water if the patient is awake and can swallow normally
• Observe for gastrointestinal irritation

Do not induce vomiting

Induced emesis is unnecessary and may cause additional harm.

Activated Charcoal

Activated charcoal is not routinely required for typical benzoyl peroxide exposures.

Gastric Lavage

The older recommendation for routine gastric lavage after large ingestion does not reflect contemporary routine poisoning management.

Supportive care and consultation with a poison center or medical toxicologist are preferable for substantial or unusual exposures.

Anaphylaxis

If severe hypersensitivity occurs:

IM epinephrine is first-line treatment.

Also provide:

• Airway management
• Oxygen when indicated
• IV fluids for hypotension
• Additional anaphylaxis therapy according to standard protocols

Antihistamines are adjuncts and should not delay epinephrine.

Antidote

There is no specific antidote for benzoyl peroxide poisoning.

Treatment is primarily:

• Decontamination
• Irrigation
• Symptom control
• Supportive care

Benzene Contamination Issue

A separate issue has involved benzene contamination or formation in some benzoyl-peroxide acne products.

In March 2025, FDA testing of 95 benzoyl-peroxide acne products found elevated benzene in six products, while more than 90% had undetectable or extremely low levels. Some products were voluntarily recalled at the retail level. FDA has noted that benzoyl peroxide can degrade to benzene under certain conditions, including extreme temperatures. (U.S. Food and Drug Administration)

This should be distinguished from acute benzoyl peroxide poisoning.

Prognosis

Most exposures cause only:

• Temporary irritation
• Dryness
• Peeling
• Contact dermatitis

Symptoms generally resolve after exposure stops and appropriate local care is provided.

Important Pitfalls

1. Confusing irritation with allergy

Mild redness, peeling, and dryness are common irritant effects.

Generalized urticaria, facial swelling, throat tightness, or respiratory compromise suggest systemic hypersensitivity.

2. Failing to irrigate eye exposures

Prompt copious irrigation is the most important initial intervention.

3. Using aggressive GI decontamination

Routine gastric lavage and activated charcoal are generally unnecessary for ordinary accidental ingestion.

4. Ignoring industrial hazards

Concentrated benzoyl peroxide is an organic peroxide with fire and explosion hazards, unlike routine dilute topical acne preparations.

High-Yield Toxicology Pearls

Benzoyl peroxide toxicity = mainly local irritation

Think:

Skin → erythema/peeling

Eyes → conjunctival/corneal irritation

Inhalation → airway irritation

Key points:

• Systemic poisoning is uncommon
• Skin irritation and dermatitis are the predominant effects
• Rare severe hypersensitivity/anaphylaxis can occur
• Eye exposure requires immediate irrigation
• Do not induce vomiting
• Routine gastric lavage is not recommended
• No specific antidote
• Current occupational limit: 5 mg/m³ TWA
• Current NIOSH IDLH: 1,500 mg/m³
• Concentrated industrial benzoyl peroxide is also a significant fire/explosion hazard

Toxicology – Benzodiazepines

Core concept

Benzodiazepines are CNS depressants used as anxiolytics, sedatives, hypnotics, anticonvulsants, muscle relaxants, and procedural/anesthetic agents.

The characteristic overdose syndrome is:

Somnolence + dysarthria + ataxia + CNS depression

In an isolated benzodiazepine overdose, severe cardiovascular or respiratory toxicity is relatively uncommon. Marked respiratory depression, coma, hypotension, or death should raise concern for:

• A very large exposure
• Significant underlying disease
• Coingestion of opioids
• Alcohol
• Other sedative-hypnotics

Benzodiazepine-related deaths most often involve other CNS depressants rather than benzodiazepines alone.

Common Benzodiazepines

Examples include:

• Alprazolam
• Chlordiazepoxide
• Clobazam
• Clonazepam
• Clorazepate
• Diazepam
• Estazolam
• Lorazepam
• Midazolam
• Nitrazepam
• Oxazepam
• Temazepam
• Triazolam

Other benzodiazepines and newer designer benzodiazepines may produce similar toxicity.

Therapeutic Uses

Benzodiazepines are used for:

• Anxiety disorders
• Acute agitation
• Insomnia
• Seizures and status epilepticus
• Alcohol withdrawal
• Muscle spasm
• Procedural sedation
• Anesthesia

Pathophysiology

Benzodiazepines bind to a specific site on the GABA-A receptor complex.

They enhance the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) and increase the frequency of chloride-channel opening.

This causes:

Cl⁻ influx → neuronal hyperpolarization → decreased neuronal excitability → CNS depression

Unlike barbiturates, benzodiazepines have a relatively wide therapeutic index when taken alone.

Toxic Dose

There is no single predictable toxic dose because toxicity varies with:

• Specific benzodiazepine
• Dose
• Age
• Tolerance
• Duration of therapy
• Liver function
• Coingestants
• Other comorbidities

Patients with chronic use may tolerate doses that would cause marked sedation in benzodiazepine-naive individuals.

Risk Factors for Severe Toxicity

Risk increases with:

• Opioid coingestion
• Alcohol
• Barbiturates
• Other sedative-hypnotics
• Advanced age
• Significant pulmonary disease
• Frailty
• Large intentional ingestion

Concurrent benzodiazepine and opioid exposure can result in profound sedation, respiratory depression, coma, and death.

Clinical Features

Neurologic

The predominant effects are:

• Drowsiness
• Somnolence
• Dysarthria
• Ataxia
• Impaired coordination
• Confusion
• Amnesia
• Hypotonia
• Reduced deep-tendon reflexes

More severe poisoning can cause:

• Stupor
• Coma
• Respiratory depression

Paradoxical effects occasionally occur, including:

• Agitation
• Restlessness
• Disinhibition
• Aggressive behavior

FDA labeling describes overdose as a spectrum from drowsiness and confusion to respiratory depression and coma.

HEENT

Possible findings include:

• Nystagmus
• Diplopia

Pupillary findings are usually not sufficiently characteristic to establish the diagnosis.

Respiratory

Possible effects include:

• Hypoventilation
• Loss of airway protective reflexes
• Aspiration
• Respiratory depression

Severe respiratory depression is much more concerning for mixed poisoning, particularly opioid or alcohol coexposure.

Cardiovascular

Isolated poisoning usually causes minimal cardiovascular disturbance.

Possible findings in severe cases include:

• Hypotension
• Bradycardia

Marked hemodynamic instability should prompt evaluation for coingestants or another diagnosis.

Temperature

Hypothermia may occur with prolonged CNS depression or environmental exposure.

Gastrointestinal

• Nausea
• Vomiting

Musculoskeletal

Prolonged unconsciousness can lead to:

• Pressure injury
• Rhabdomyolysis
• Skin necrosis

Diagnosis

Benzodiazepine poisoning is primarily a clinical diagnosis.

Think of:

CNS depression + ataxia/dysarthria + relatively preserved vital signs

while always considering mixed ingestion.

Essential Evaluation

Initial assessment should focus on:

• Airway
• Respiratory rate
• Oxygenation
• Ventilation
• Blood pressure
• Mental status
• Blood glucose

Minimally symptomatic patients may require little laboratory testing.

Recommended Investigations

In clinically significant poisoning consider:

• Point-of-care glucose
• Pulse oximetry
• Capnography when available
• Serum electrolytes
• BUN
• Creatinine
• ECG

In intentional overdose consider screening for common dangerous coingestants such as:

• Acetaminophen
• Salicylates
• Ethanol when relevant

If prolonged coma occurs:

• CK
• Urinalysis
• Renal function

Additional testing such as CT brain or infectious evaluation should be based on the differential diagnosis.

Benzodiazepine Drug Testing

Quantitative serum benzodiazepine concentrations generally do not correlate sufficiently with clinical severity to guide acute treatment.

Urine immunoassays also have important limitations and may not reliably detect every benzodiazepine.

Therefore:

Treat the patient, not the benzodiazepine level.

Differential Diagnosis

Toxicologic

Consider:

• Opioids
• Ethanol
• Barbiturates
• Other sedative-hypnotics
• Antipsychotics
• Antidepressants
• Anticonvulsants
• Gamma-hydroxybutyrate
• Clonidine

Non-toxicologic

Consider:

• Hypoglycemia
• Hypoxia
• Intracranial hemorrhage
• Head trauma
• Meningitis
• Encephalitis
• Postictal state
• Electrolyte abnormalities
• Metabolic encephalopathy

Treatment

1. Supportive Care

Supportive care is the mainstay of treatment.

Most isolated benzodiazepine overdoses recover with:

• Observation
• Airway support
• Respiratory monitoring
• Hemodynamic support

Current toxicology references emphasize that supportive treatment is sufficient for most isolated overdoses.

2. Airway and Breathing

Assess airway protective reflexes and ventilation.

Provide:

• Supplemental oxygen when indicated
• Bag-mask ventilation if necessary
• Endotracheal intubation for significant respiratory failure or inability to protect the airway

Capnography can be useful for detecting hypoventilation before marked hypoxemia develops.

3. Suspected Opioid Coingestion

When opioid and benzodiazepine coexposure is possible in a patient with significant respiratory depression:

Naloxone should generally be given before considering flumazenil.

The American Heart Association specifically recommends naloxone first when combined opioid-benzodiazepine poisoning is suspected.

4. Hypotension

If hypotension occurs:

• Give isotonic IV crystalloid
• Reassess frequently
• Use vasopressor therapy if hypotension persists despite appropriate fluid resuscitation

Profound or refractory hypotension is unusual in isolated benzodiazepine poisoning and should prompt investigation for additional toxicants.

Gastrointestinal Decontamination

Older references recommended routine activated charcoal or gastric lavage.

This is not current routine management.

Because benzodiazepine poisoning commonly produces sedation and loss of airway protection, GI decontamination creates an important aspiration risk.

Current toxicology guidance states that:

• Activated charcoal generally has no routine role
• Whole-bowel irrigation has no role
• Gastric lavage is not routinely indicated

Supportive care is usually safer and sufficient.

Do not induce vomiting.

Antidote – Flumazenil

Flumazenil is a competitive benzodiazepine-receptor antagonist.

It can rapidly reverse:

• Sedation
• CNS depression
• Some benzodiazepine-associated respiratory depression

However:

Flumazenil should NOT be routinely administered to patients with suspected benzodiazepine overdose.

The risks frequently outweigh the benefits in undifferentiated or intentional overdose.

When Flumazenil May Be Appropriate

Flumazenil may be considered in carefully selected low-risk patients, such as:

• Excessive benzodiazepine sedation during a medical procedure
• Known isolated benzodiazepine exposure
• Benzodiazepine-naive patient
• Selected accidental pediatric ingestions
• Significant respiratory depression clearly attributable to a benzodiazepine when contraindications have been excluded

The AHA considers flumazenil potentially effective for pure benzodiazepine poisoning in carefully selected adults and children without contraindications.

When Flumazenil Should Be Avoided

Major concerns include:

• Chronic benzodiazepine use or dependence
• Known seizure disorder
• Benzodiazepines being used to control seizures
• Unknown or mixed overdose
• Tricyclic antidepressant coingestion
• Other proconvulsant coingestants
• ECG findings suggesting sodium-channel-blocking toxicity
• High risk of withdrawal

Flumazenil can precipitate:

• Acute benzodiazepine withdrawal
• Seizures
• Dysrhythmias
• Severe agitation

These risks are particularly important in benzodiazepine-dependent patients and mixed overdoses.

Flumazenil Dosing

When specialist assessment determines that flumazenil is appropriate for a suspected adult benzodiazepine overdose, FDA labeling describes an initial:

0.2 mg IV over approximately 30 seconds

If necessary, additional titrated doses can be given to clinical effect rather than immediately administering a large bolus. Patients require airway readiness and monitoring for recurrence of sedation and seizures.

Resedation

Flumazenil has a shorter duration of action than many benzodiazepines.

Therefore:

Sedation and respiratory depression may recur after initial reversal.

Patients receiving flumazenil require continued monitoring for:

• Resedation
• Respiratory depression
• Withdrawal
• Seizures

Cardiac Arrest

Flumazenil has no role in benzodiazepine-associated cardiac arrest.

Standard resuscitation and treatment of reversible causes take priority.

Hemodialysis

Hemodialysis is not useful for routine benzodiazepine poisoning because these agents generally have:

• High protein binding
• Large volumes of distribution

Extracorporeal removal is therefore ineffective for most benzodiazepines.

Monitoring

Significantly symptomatic patients should receive:

• Continuous respiratory monitoring
• Pulse oximetry
• Consideration of capnography
• Serial mental-status examinations
• Hemodynamic monitoring

Continuous cardiac monitoring is appropriate in severe cases or suspected mixed overdose.

Admission

Hospital admission is appropriate for:

• Persistent CNS depression
• Significant respiratory depression
• Recurrent sedation
• Need for mechanical ventilation
• Hemodynamic instability
• Significant mixed overdose
• Complications such as aspiration or rhabdomyolysis

Severe poisoning generally requires ICU-level care.

Disposition

Patients may be considered for discharge when:

• Mental status has returned to baseline
• Ambulation is safe
• Respiratory status is normal
• Vital signs are stable
• No delayed toxicity from coingestants is expected

Intentional overdose requires appropriate mental-health and safety assessment before disposition.

Observation time should be individualized according to:

• Specific agent
• Formulation
• Dose
• Clinical course
• Coingestants
• Patient age and comorbidities

Long-acting agents may require longer monitoring.

Expected Course and Prognosis

The prognosis after an isolated benzodiazepine overdose is generally excellent with appropriate supportive care.

Most morbidity and mortality result from:

• Opioid coingestion
• Alcohol
• Other CNS depressants
• Aspiration
• Prolonged hypoxia
• Trauma related to intoxication

Benzodiazepine Withdrawal

Chronic benzodiazepine therapy should not be abruptly discontinued.

Withdrawal can cause:

• Anxiety
• Insomnia
• Tremor
• Agitation
• Autonomic hyperactivity
• Hallucinations
• Seizures
• Delirium

This is one reason flumazenil can be hazardous in dependent patients.

Pregnancy and Lactation

The older FDA pregnancy categories A, B, C, D, and X are obsolete.

The FDA removed these letter categories under the Pregnancy and Lactation Labeling Rule and replaced them with individualized sections describing:

• Pregnancy risk
• Clinical considerations
• Available human and animal data
• Lactation considerations

Pregnancy decisions therefore depend on the individual benzodiazepine, indication, dose, timing, and maternal-fetal risk rather than an old letter category.

Important Pitfalls

1. Assuming profound respiratory depression is due to benzodiazepines alone

Severe respiratory compromise should prompt immediate consideration of:

• Opioids
• Alcohol
• Other sedative drugs

2. Routine use of flumazenil

Flumazenil can cause seizures and dangerous withdrawal.

It is reserved for carefully selected patients.

3. Giving flumazenil in an unknown mixed overdose

Benzodiazepines may be suppressing seizures caused by another toxicant. Reversing that protective effect can precipitate severe toxicity.

4. Missing opioid coexposure

When respiratory depression is present and opioid exposure is possible:

Give naloxone before considering flumazenil.

5. Routine activated charcoal or gastric lavage

The aspiration risk generally outweighs potential benefit in benzodiazepine poisoning.

6. Relying on benzodiazepine levels

Serum concentrations rarely guide acute management.

7. Abruptly stopping chronic therapy

Withdrawal can cause delirium and seizures.

High-Yield Toxicology Pearls

Benzodiazepine overdose = CNS depression with relatively preserved cardiovascular function

Think:

Somnolence + dysarthria + ataxia + hyporeflexia

Key points:

• Mechanism: GABA-A receptor potentiation
• Benzodiazepines increase the frequency of chloride-channel opening
• Isolated overdose usually causes CNS depression rather than profound cardiovascular collapse
• Severe respiratory depression suggests coingestion, especially opioids or alcohol
• Main treatment: supportive airway and respiratory care
• Routine gastric lavage and activated charcoal are not recommended
• Hemodialysis is ineffective
• Flumazenil is not routinely used
• Flumazenil can trigger withdrawal, seizures, and dysrhythmias
• Avoid flumazenil in chronic benzodiazepine users, seizure-prone patients, and unknown/mixed overdoses
• In suspected opioid-benzodiazepine poisoning with respiratory depression, naloxone comes first
• Long-acting benzodiazepines may cause prolonged sedation
• Most isolated overdoses recover completely with supportive care

Toxicology – Benzocaine

Core concept

Benzocaine is an ester local anesthetic that can cause acquired methemoglobinemia.

The hallmark toxicity is:

Benzocaine exposure → oxidation of hemoglobin Fe²⁺ to Fe³⁺ → methemoglobinemia → impaired oxygen delivery → tissue hypoxia

A characteristic presentation is:

Cyanosis that does not improve adequately with oxygen + relatively normal PaO₂ + chocolate-brown blood

Forms and Uses

Benzocaine is found in numerous topical preparations, including:

• Oral gels and liquids
• Toothache preparations
• Throat sprays and lozenges
• Topical creams and ointments
• Aerosol anesthetic sprays
• Otic preparations
• Hemorrhoidal preparations

It may also occasionally be encountered as an adulterant in illicit drugs.

Pediatric Warning

Infants and young children are particularly susceptible to benzocaine-induced methemoglobinemia.

The FDA advises that benzocaine-containing oral products should not be used in children younger than 2 years, particularly for teething pain. Benzocaine provides little benefit for teething and can cause potentially fatal methemoglobinemia.

Toxic Dose

There is no reliably safe dose that excludes methemoglobinemia.

Toxicity has occurred:

• After overdose
• After repeated topical application
• After excessive mucosal application
• Occasionally after apparently therapeutic use

The older source reports toxicity in infants after ingestion of only 1–2 mL of 7.5% benzocaine gel.

Susceptibility varies considerably among individuals.

Pathophysiology

Benzocaine is metabolized to oxidizing metabolites capable of converting normal hemoglobin iron:

Fe²⁺ → Fe³⁺

This produces methemoglobin, which cannot effectively bind and transport oxygen.

Normally:

Methemoglobin → reduced back to functional hemoglobin primarily by cytochrome-b5 reductase

When oxidation overwhelms the body’s reducing capacity:

Methemoglobin accumulates → functional anemia + impaired tissue oxygen delivery

Remaining normal hemoglobin also holds oxygen more tightly, further reducing oxygen delivery to tissues.

Risk Factors

Greater susceptibility occurs in:

• Infants, particularly <6 months
• Excessive or repeated benzocaine application
• Application to damaged or highly vascular mucosa
• Anemia
• Significant cardiac disease
• Significant pulmonary disease
• Concurrent oxidizing medications or chemicals
• Congenital methemoglobin-reduction disorders

Young infants have lower methemoglobin-reductase activity and therefore greater susceptibility.

Clinical Features

Symptoms result primarily from functional hypoxia.

Characteristic finding

Central cyanosis despite supplemental oxygen

The skin, lips, and nail beds may appear:

• Blue
• Gray
• Slate-colored

Approximate Severity by Methemoglobin Level

Clinical effects vary, but approximate patterns are:

• <10%: usually asymptomatic
• 10–20%: cyanosis may become apparent
• 20–30%: headache, fatigue, dyspnea, lightheadedness
• 30–50%: tachycardia, confusion, weakness, worsening dyspnea
• 50–70%: severe CNS and cardiovascular toxicity, seizures, dysrhythmias, coma
• >70%: often life-threatening or fatal

Symptoms may occur at lower levels in patients with anemia or significant heart/lung disease.

Cardiovascular

Significant methemoglobinemia may cause:

• Tachycardia
• Hypotension
• Dysrhythmias
• Myocardial ischemia
• Cardiovascular collapse

Pulmonary

Possible manifestations include:

• Dyspnea
• Tachypnea
• Subjective air hunger
• Cyanosis

The problem is impaired oxygen carriage, not necessarily failure of oxygen to enter the lungs.

Neurologic

Progressive hypoxia may cause:

• Headache
• Dizziness
• Anxiety
• Confusion
• Altered mental status
• Seizures
• Coma

Gastrointestinal

• Nausea
• Vomiting

Metabolic

Severe tissue hypoxia may produce:

Lactic acidosis

Dermatologic

Topical benzocaine can also cause:

• Local irritation
• Rash
• Contact hypersensitivity

Diagnosis

The definitive diagnostic test is:

Blood methemoglobin concentration measured by co-oximetry

Normal methemoglobin is generally <1–2%, although laboratory reference ranges vary.

The Classic Diagnostic Clues

1. Cyanosis resistant to oxygen

The patient remains cyanotic despite adequate supplemental oxygen.

2. Chocolate-brown blood

Blood may appear:

Dark chocolate brown

and does not become normally bright red after exposure to oxygen.

3. Normal PaO₂ despite apparent hypoxia

A crucial point:

PaO₂ measures dissolved oxygen in plasma, not oxygen carried by hemoglobin.

Therefore, a patient may have:

• Normal or high PaO₂
• Severe tissue hypoxia from methemoglobinemia

4. Pulse oximetry may be misleading

Standard pulse oximetry cannot accurately quantify methemoglobinemia.

As methemoglobin increases, SpO₂ often trends toward approximately 85%, regardless of the true degree of oxygenation.

Thus:

A normal or near-normal pulse oximeter reading does not reliably exclude clinically important methemoglobinemia.

Saturation Gap

A useful clue is a discrepancy between:

• Pulse oximeter saturation
• Calculated oxygen saturation obtained from an arterial blood gas

This is sometimes called a saturation gap.

Co-oximetry is required for definitive measurement.

Investigations

For symptomatic patients consider:

• Co-oximetry with methemoglobin level
• Blood gas
• Serum electrolytes
• Bicarbonate
• BUN
• Creatinine
• Lactate
• ECG
• Continuous cardiac monitoring

Consider CBC if anemia or hemolysis is suspected.

Benzocaine Levels

Blood or urine benzocaine concentrations are generally not clinically useful for acute management.

Treatment is guided by:

• Clinical condition
• Methemoglobin level
• Evidence of tissue hypoxia

Differential Diagnosis

Other causes of acquired methemoglobinemia include:

• Dapsone
• Nitrites and nitrates
• Aniline compounds
• Phenazopyridine
• Primaquine
• Sulfonamides
• Chlorates
• Naphthalene
• Some local anesthetics

Other causes of cyanosis should also be considered.

Sulfhemoglobinemia

Sulfhemoglobinemia may resemble methemoglobinemia clinically.

Consider it particularly when:

• Cyanosis persists
• Co-oximetry findings are atypical
• There is poor or absent response to methylene blue

Treatment

1. Stop Benzocaine Exposure

Immediately discontinue the offending product.

For dermal exposure:

• Remove contaminated material
• Wash the skin thoroughly with soap and water

For mucosal exposure:

• Remove residual product when practical

2. Oxygen

Administer high-concentration oxygen to symptomatic patients.

Oxygen does not directly convert methemoglobin back to normal hemoglobin, but it maximizes:

• Oxygen carried by remaining functional hemoglobin
• Dissolved plasma oxygen

while definitive treatment is initiated.

3. Methylene Blue

Methylene blue is the primary antidotal treatment for clinically significant acquired methemoglobinemia.

Treatment is based primarily on the patient’s clinical status, not solely on a numerical methemoglobin concentration.

Consider treatment for:

• Neurologic symptoms
• Dyspnea or significant respiratory distress
• Chest pain
• Hypotension
• Significant acidosis
• Other evidence of tissue hypoxia

Treatment is also commonly considered when methemoglobin concentrations are approximately 20–30% or greater, with a lower threshold in patients with:

• Significant anemia
• Cardiovascular disease
• Pulmonary disease

Dose

Methylene blue 1–2 mg/kg IV over approximately 5 minutes

A clinical response usually occurs rapidly.

If significant symptoms or methemoglobinemia persist, the dose may be repeated after approximately 30–60 minutes.

Mechanism of Methylene Blue

Methylene blue is reduced to leukomethylene blue through an NADPH-dependent pathway.

Leukomethylene blue then reduces:

Fe³⁺ methemoglobin → Fe²⁺ functional hemoglobin

G6PD Deficiency

Methylene blue requires adequate NADPH production.

In G6PD deficiency:

• Response to methylene blue may be inadequate
• Methylene blue can precipitate or worsen hemolysis

Therefore, significant known G6PD deficiency requires specialist toxicology/hematology input and consideration of alternative treatment.

Importantly, treatment of a critically hypoxic patient should not necessarily be delayed while waiting for a G6PD test result.

Excessive Methylene Blue

Large cumulative doses may paradoxically act as an oxidizing agent and can:

• Worsen methemoglobinemia
• Produce hemolysis

The risk rises with excessive cumulative dosing.

Serotonin Syndrome

Methylene blue also inhibits monoamine oxidase-A.

Therefore, patients taking serotonergic drugs may be at risk of serotonin toxicity when methylene blue is administered.

In severe, life-threatening methemoglobinemia, treatment decisions must balance this risk against the immediate danger of tissue hypoxia.

Refractory Methemoglobinemia

If severe methemoglobinemia does not respond adequately to methylene blue, consider specialist-directed therapy such as:

• Exchange transfusion
• Hyperbaric oxygen in selected cases

These approaches are particularly relevant when methylene blue is ineffective or contraindicated.

Ascorbic Acid

Ascorbic acid can reduce methemoglobin but works much more slowly than methylene blue.

It is not the preferred treatment for rapidly progressive, life-threatening methemoglobinemia, but may have a role in selected circumstances when methylene blue cannot be used.

Gastrointestinal Decontamination

Do not induce vomiting

Emesis should not be induced because neurologic deterioration or seizures may occur and aspiration is possible.

Activated Charcoal

Activated charcoal may be considered after a significant recent ingestion when:

• The airway is intact or protected
• Presentation is early
• Aspiration risk is acceptable

Routine gastric lavage is generally not recommended in contemporary poisoning management.

Monitoring

Symptomatic patients should receive:

• Continuous cardiac monitoring
• Pulse oximetry
• Repeated neurologic assessment
• Serial methemoglobin concentrations

After methylene blue:

• Repeat the methemoglobin level
• Monitor clinical response
• Watch for recurrent methemoglobinemia

Rebound Methemoglobinemia

Methemoglobinemia can recur when:

• Benzocaine absorption continues
• A large exposure occurred
• Repeated topical application occurred
• Other oxidizing substances are present

Therefore, clinical improvement after methylene blue does not always eliminate the need for continued observation.

Admission

Hospital admission is appropriate for:

• Symptomatic methemoglobinemia
• Significant elevation of methemoglobin
• Methylene blue treatment
• Hemodynamic instability
• Seizures
• Significant acidosis
• Recurrent methemoglobinemia

Severe cases require ICU-level care.

Prognosis

Most patients recover rapidly when:

• Exposure is stopped
• Methemoglobinemia is recognized early
• Appropriate treatment is given before prolonged tissue hypoxia develops

Poor outcomes may result from:

• Delayed recognition
• Severe prolonged hypoxia
• Seizures
• Cardiovascular collapse
• Significant hemolysis

Important Pitfalls

1. Trusting the PaO₂

A normal PaO₂ does not exclude methemoglobinemia.

PaO₂ reflects dissolved oxygen rather than hemoglobin oxygen-carrying capacity.

2. Trusting pulse oximetry

Pulse oximetry is unreliable for quantifying methemoglobinemia.

Use co-oximetry.

3. Delaying methylene blue in severe symptomatic toxicity

When severe methemoglobinemia is strongly suspected, treatment should not be delayed solely while awaiting confirmatory testing.

4. Missing recurrent toxicity

Methemoglobin levels can rise again after apparently successful treatment.

5. Giving excessive methylene blue

High doses can paradoxically worsen methemoglobinemia and cause hemolysis.

6. Missing G6PD deficiency

Methylene blue may be ineffective and increase hemolysis risk in significant G6PD deficiency.

7. Using benzocaine for infant teething

The FDA advises against benzocaine-containing oral products in children younger than 2 years because of the risk of serious or fatal methemoglobinemia.

High-Yield Toxicology Pearls

Benzocaine = acquired methemoglobinemia

Think:

Benzocaine exposure + cyanosis + chocolate-brown blood + normal PaO₂ → METHEMOGLOBINEMIA

Key points:

• Benzocaine oxidizes hemoglobin Fe²⁺ → Fe³⁺
• Methemoglobin cannot effectively transport oxygen
• Cyanosis may fail to improve with oxygen
• PaO₂ can remain normal
• Standard pulse oximetry is unreliable and often approaches ~85%
• Diagnosis: co-oximetry
• Main antidote: methylene blue
• Dose: 1–2 mg/kg IV over ~5 minutes
• Repeat after 30–60 minutes if clinically necessary
• Methylene blue may cause hemolysis or be ineffective in G6PD deficiency
• Methylene blue can interact with serotonergic medications
• Severe refractory cases may require exchange transfusion or hyperbaric oxygen
• Rebound methemoglobinemia may occur
• Do not use benzocaine oral products for teething in children under 2 years

Toxicology – Benzene

Core concept

Benzene is a volatile aromatic hydrocarbon and an important industrial solvent/chemical intermediate.

Its toxicity differs markedly between acute and chronic exposure:

Acute exposure → CNS depression + respiratory compromise + cardiac dysrhythmias

Chronic exposure → bone-marrow suppression + hematologic malignancy

The bone marrow is the major target organ of chronic benzene toxicity.

Forms and Uses

Benzene (C₆H₆) is used extensively as a chemical intermediate in the manufacture of:

• Plastics and resins
• Synthetic rubber
• Dyes
• Pharmaceuticals
• Detergents
• Lubricants
• Pesticides and other agricultural chemicals

Benzene may also be encountered in:

• Gasoline
• Petroleum products
• Paints
• Solvents
• Adhesives
• Industrial emissions
• Tobacco smoke

Cumene, styrene, and cyclohexane are separate chemicals rather than forms of benzene, although they are industrially related to benzene.

Absorption and Metabolism

Benzene is:

• Rapidly absorbed through the lungs
• Absorbed through the gastrointestinal tract
• Absorbed more slowly through intact skin

It is metabolized mainly by hepatic cytochrome P450 enzymes, particularly to reactive metabolites that subsequently undergo further metabolism in the liver and bone marrow.

These metabolites contribute to:

• Oxidative stress
• Chromosomal injury
• DNA damage
• Bone-marrow toxicity
• Carcinogenesis

Pathophysiology

Acute Exposure

High concentrations primarily affect the:

CNS + cardiovascular system + respiratory system

Acute toxicity can produce:

Initial CNS excitation → CNS depression → respiratory failure/coma

Benzene may also sensitize the myocardium to catecholamines, increasing the risk of ventricular dysrhythmias and sudden death.

Chronic Exposure

Reactive benzene metabolites damage hematopoietic stem and progenitor cells.

This can cause:

Bone-marrow suppression → cytopenias → aplastic anemia/pancytopenia

Long-term exposure is also associated with leukemia.

ATSDR identifies hematotoxicity, immunotoxicity, and hematopoietic malignancy as well-established consequences of benzene exposure.

Carcinogenicity

Benzene is carcinogenic to humans — IARC Group 1.

There is sufficient human evidence that benzene causes acute myeloid leukemia (AML) in adults. Associations have also been reported with several other hematologic malignancies, although the strength of evidence differs among individual cancers.

This is one of the most important long-term toxicologic features of benzene.

Occupational Exposure Limits

Current U.S. occupational standards differ substantially from the older values in the source text.

OSHA

• 8-hour TWA: 1 ppm
• 15-minute STEL: 5 ppm

NIOSH

• TWA: 0.1 ppm
• STEL: 1 ppm
• IDLH: 500 ppm

The older OSHA value of 10 ppm TWA is outdated; OSHA reduced the benzene TWA limit to 1 ppm decades ago.

Clinical Features

Acute Benzene Poisoning

Neurologic

Acute exposure may initially cause CNS stimulation:

• Euphoria
• Headache
• Dizziness
• Tremor
• Ataxia
• Confusion
• Nystagmus

Progressive poisoning may produce:

• Somnolence
• Vertigo
• Severe confusion
• Seizures
• Coma
• Respiratory depression

A historically described occupational syndrome, sometimes called a “benzol jag,” consists of acute euphoria, confusion, and ataxia.

Cardiovascular

Possible findings include:

• Tachycardia
• Palpitations
• Ventricular dysrhythmias
• Hypotension
• Cardiovascular collapse

Sudden death after massive inhalational exposure may result from a combination of:

• Myocardial sensitization
• Ventricular dysrhythmia
• Hypoxia
• Respiratory depression

Pulmonary

Possible effects include:

• Cough
• Respiratory irritation
• Respiratory depression

After ingestion, vomiting followed by aspiration can cause chemical pneumonitis.

Gastrointestinal

Ingestion can cause:

• Nausea
• Vomiting
• Abdominal discomfort
• Gastrointestinal irritation

Eyes

Liquid exposure can cause:

• Lacrimation
• Conjunctival irritation
• Blepharospasm
• Corneal injury

Skin

Repeated or prolonged contact may cause:

• Irritant dermatitis
• Defatting of the skin
• Occasionally more significant chemical injury

Chronic Benzene Toxicity

Hematologic

The most important chronic manifestations are:

• Anemia
• Leukopenia
• Thrombocytopenia
• Pancytopenia
• Bone-marrow hypoplasia
• Aplastic anemia

Benzene-associated disruption of hematopoiesis can reduce erythrocytes, leukocytes, platelets, and hematopoietic progenitor cells.

Malignancy

Most importantly:

• Acute myeloid leukemia

IARC classifies benzene as a Group 1 human carcinogen.

Diagnosis

Diagnosis depends primarily on:

Exposure history + clinical syndrome

There is no single routinely useful serum benzene concentration that guides emergency management.

Acute Exposure Investigations

Minimally symptomatic patients may require little laboratory testing.

For significant exposure consider:

• ECG
• Continuous cardiac monitoring
• Pulse oximetry
• Blood gas when indicated
• Serum electrolytes
• Glucose
• BUN
• Creatinine

If pulmonary aspiration or respiratory symptoms are present:

• Chest radiograph

In intentional ingestion or unexplained CNS depression:

• Evaluate for relevant coingestants
• Consider acetaminophen and salicylate levels

Chronic Exposure Investigations

For suspected chronic toxicity:

• CBC with differential
• Reticulocyte count
• Peripheral blood smear
• Renal function
• Liver function tests

Persistent cytopenias may require:

• Hematology consultation
• Bone-marrow evaluation

Biomarkers

Benzene and its metabolites may be measured for occupational or exposure assessment, but they are generally not useful for guiding immediate treatment of acute poisoning.

Differential Diagnosis

Acute CNS Depression

Consider:

• Alcohol
• Opioids
• Benzodiazepines
• Sedative-hypnotics
• Other hydrocarbon solvents
• Carbon monoxide
• Hypoglycemia
• Hypoxia
• Intracranial disease
• Electrolyte disorders

Bone-Marrow Suppression

Consider:

• Hematologic malignancy
• Medications
• Ionizing radiation
• Other industrial chemicals
• Nutritional deficiencies
• Viral disease
• Autoimmune disorders

Treatment

1. Remove from Exposure

For inhalational exposure:

Immediately remove the patient to fresh air.

Provide supplemental oxygen when indicated.

CDC recommends rapid removal from the source because inhaled benzene can cause neurologic and cardiovascular toxicity within minutes to hours.

2. Airway and Breathing

Assess:

• Airway protection
• Respiratory rate
• Oxygenation
• Ventilation

Severe CNS depression may require:

• Endotracheal intubation
• Mechanical ventilation

Cardiovascular Management

Establish:

• IV access
• Continuous ECG monitoring
• Hemodynamic monitoring

Treat hypotension initially with:

• IV isotonic crystalloid

Dysrhythmias

Treat clinically significant dysrhythmias with appropriate advanced supportive care.

Because benzene can sensitize the myocardium to catecholamines, unnecessary catecholamine administration should be avoided, particularly epinephrine given specifically to treat dysrhythmias. NIOSH specifically advises avoiding epinephrine for benzene-associated arrhythmias because of this myocardial sensitization.

Seizures

Treat seizures with:

Benzodiazepines

while simultaneously correcting hypoxia and other physiologic abnormalities.

Decontamination

Inhalational Exposure

• Remove from contaminated environment
• Give oxygen as clinically indicated
• Protect rescuers from exposure

Skin Exposure

Remove contaminated clothing and wash exposed skin thoroughly with:

• Soap
• Water

CDC currently recommends removing contaminated clothing and washing the body after significant liquid benzene exposure.

Eye Exposure

Immediately irrigate with copious water or saline for at least approximately 15 minutes and evaluate persistent ocular injury.

Ingestion

Do not induce vomiting

Emesis should not be induced.

Benzene is volatile and aspiration can cause serious pulmonary injury.

Activated Charcoal

Activated charcoal has limited ability to reduce gastrointestinal benzene absorption and is not a central component of treatment.

Gastric Lavage

The older source recommends routine gastric lavage after large recent ingestion.

This should not be interpreted as routine modern management because benzene carries a substantial aspiration risk.

If a very large ingestion has occurred, gastric aspiration/decontamination should only be considered selectively after:

• Airway protection
• Toxicology consultation
• Careful assessment of aspiration risk

NIOSH notes that gastric aspiration may be considered after the airway has been secured.

Antidote

There is no specific antidote for benzene poisoning.

Treatment is primarily:

Removal from exposure + airway support + oxygenation + cardiovascular monitoring + supportive care.

Chronic Exposure Management

For chronic occupational exposure:

• Remove or reduce further exposure
• Perform serial CBC monitoring
• Evaluate persistent cytopenias
• Refer to occupational medicine when appropriate
• Obtain hematology evaluation for significant abnormalities

Patients should be educated about the long-term hematologic and carcinogenic risks of benzene exposure.

Monitoring

Symptomatic acute exposures warrant:

• Continuous ECG monitoring
• Pulse oximetry
• Serial neurologic assessment
• Blood-pressure monitoring
• Respiratory monitoring

Chronic exposure requires:

• Serial CBC with differential
• Assessment for persistent or progressive cytopenias

Admission

Hospital admission is appropriate when there is:

• Persistent CNS depression
• Respiratory compromise
• Significant aspiration
• Seizures
• Hypotension
• Cardiac dysrhythmia
• Other significant systemic toxicity

Severe poisoning generally requires ICU-level management.

Prognosis

Acute Exposure

Mild inhalational symptoms may resolve rapidly after removal from exposure.

Massive exposure can cause:

• Coma
• Respiratory arrest
• Ventricular dysrhythmia
• Sudden death

Chronic Exposure

Potential long-term consequences include:

• Persistent cytopenias
• Aplastic anemia
• Bone-marrow failure
• Leukemia

Important Pitfalls

1. Missing cardiac dysrhythmias

Benzene can sensitize the myocardium to catecholamines and produce sudden ventricular arrhythmias.

2. Inducing vomiting

Vomiting markedly increases the risk of hydrocarbon aspiration and chemical pneumonitis.

3. Overreliance on pulse oximetry alone

A patient with severe CNS depression or hypoventilation requires assessment of ventilation as well as oxygenation.

4. Focusing only on acute CNS toxicity

The major consequence of chronic exposure is hematopoietic toxicity.

5. Missing occupational follow-up

Persistent benzene exposure warrants hematologic and occupational-health surveillance.

6. Using outdated workplace standards

The current OSHA benzene limits are:

1 ppm TWA and 5 ppm STEL, not the older 10-ppm TWA value contained in the source text.

High-Yield Toxicology Pearls

Benzene = acute CNS/cardiac toxicity + chronic bone-marrow toxicity

Think:

Acute high-dose exposure → CNS depression + dysrhythmia

versus

Chronic exposure → pancytopenia/aplastic anemia + AML

Key points:

• Benzene is a volatile aromatic hydrocarbon
• Acute toxicity primarily affects the CNS and cardiovascular system
• Severe exposure may cause coma, respiratory arrest, and ventricular dysrhythmias
• Myocardial sensitization makes excessive catecholamine exposure potentially hazardous
• Aspiration after ingestion can cause chemical pneumonitis
• Do not induce vomiting
• No specific antidote
• Chronic toxicity primarily targets the bone marrow
• Chronic exposure may cause anemia, leukopenia, thrombocytopenia, and pancytopenia
• Benzene is an IARC Group 1 human carcinogen
• The strongest established malignancy association is acute myeloid leukemia
• Current OSHA limit: 1 ppm 8-hour TWA; 5 ppm 15-minute STEL
• Current NIOSH REL: 0.1 ppm TWA; 1 ppm STEL
• NIOSH IDLH: 500 ppm

Toxicology – Bee Stings

Core concept

Bee, wasp, yellow-jacket, and hornet stings cause toxicity by two distinct mechanisms:

1. IgE-mediated anaphylaxis – may occur after a single sting in a sensitized patient and is not dose-dependent
2. Massive envenomation – direct venom toxicity after numerous stings and is dose-dependent

This distinction is critical:

Single sting + rapid airway/circulatory symptoms → think anaphylaxis

Many stings + delayed systemic organ injury → think massive envenomation

Important Species

Clinically important Hymenoptera include:

• European honey bee (Apis mellifera)
• Africanized honey bee
• Wasps
• Yellow jackets
• Hornets

Africanized bees are dangerous mainly because they:

• Defend colonies aggressively
• Attack in large numbers
• May pursue victims

Their venom is not substantially more potent than ordinary honey-bee venom; the major danger is massive venom delivery from multiple simultaneous stings.

Toxic Dose

Anaphylaxis

One sting can be fatal in a highly sensitized individual.

The severity of an allergic reaction does not depend on the number of stings.

Massive envenomation

Direct systemic toxicity generally requires numerous stings.

Systemic toxic reactions have been described with approximately 50 or more simultaneous bee stings, while several hundred may cause life-threatening toxicity in adults. Children may develop severe toxicity with substantially fewer stings because of their lower body mass.

Pathophysiology

1. Allergic / Anaphylactic Reaction

Venom triggers an IgE-mediated hypersensitivity reaction:

Venom exposure → mast-cell/basophil activation → mediator release → vasodilation + capillary leak + bronchospasm + airway edema

This may rapidly cause:

• Urticaria
• Angioedema
• Bronchospasm
• Hypotension
• Shock
• Airway obstruction

2. Massive Envenomation

Large quantities of venom produce direct cellular and organ toxicity.

Major venom-related complications include:

• Rhabdomyolysis
• Intravascular hemolysis
• Acute kidney injury
• Myocardial injury
• Hepatic injury
• Shock

Acute kidney injury may result from a combination of hypotension, myoglobinuria, hemoglobinuria, and direct tubular venom toxicity.

Clinical Features

Local Reaction

Most stings cause:

• Immediate burning pain
• Erythema
• Local swelling
• Wheal-and-flare reaction
• Pruritus

Large local reactions may produce extensive swelling lasting several days.

Anaphylaxis

Symptoms usually develop rapidly.

Dermatologic

• Generalized urticaria
• Flushing
• Pruritus
• Angioedema

Importantly, anaphylaxis can occur without skin findings.

Airway

• Throat tightness
• Tongue or laryngeal edema
• Hoarseness
• Stridor
• Upper-airway obstruction

Pulmonary

• Chest tightness
• Wheezing
• Bronchospasm
• Respiratory distress
• Hypoxemia

Cardiovascular

• Tachycardia
• Hypotension
• Shock
• Collapse

Severe anaphylaxis may rapidly progress to cardiac arrest.

Gastrointestinal

• Nausea
• Vomiting
• Abdominal cramping
• Diarrhea

Massive Envenomation

Patients may initially have extensive local pain and swelling followed by systemic toxicity.

Possible manifestations include:

• Nausea and vomiting
• Diarrhea
• Generalized weakness
• Headache
• Altered mental status
• Hypotension or cardiovascular collapse
• Rhabdomyolysis
• Hemolysis
• Acute kidney injury
• Hepatic injury
• Myocardial injury
• Coma

Some systemic complications, particularly rhabdomyolysis and acute kidney injury, may worsen over the following 24–48 hours rather than appearing immediately.

Diagnosis

Diagnosis is usually clinical:

History of sting(s) + local findings ± allergic or systemic manifestations

No laboratory testing is usually needed for an uncomplicated local reaction.

Investigations in Systemic Reactions

Consider:

• CBC
• Serum electrolytes
• BUN
• Creatinine
• Glucose
• Creatine kinase
• Liver enzymes
• LDH
• Bilirubin
• Urinalysis
• ECG

If significant respiratory compromise is present:

• Pulse oximetry
• Blood gas when indicated

In massive envenomation, specifically monitor for:

• Rhabdomyolysis
• Hemolysis
• Acute kidney injury
• Hyperkalemia
• Metabolic acidosis

Treatment

Anaphylaxis

1. Epinephrine — First-Line Treatment

Intramuscular epinephrine is the treatment of choice for anaphylaxis.

Give into the anterolateral thigh.

Typical dosing:

• Adults: 0.5 mg IM of 1 mg/mL (1:1000) epinephrine
• Children: approximately 0.01 mg/kg IM, using age/weight-appropriate dosing

If airway, breathing, or circulatory problems persist, repeat IM epinephrine after approximately 5 minutes. Current resuscitation guidance identifies IM epinephrine as first-line treatment; IV epinephrine is reserved for appropriately monitored refractory cases managed by experienced clinicians.

The older source’s routine IV epinephrine bolus regimen should not be used as routine first-line treatment for anaphylaxis.

2. Airway

Assess immediately for:

• Stridor
• Hoarseness
• Tongue swelling
• Progressive facial/neck swelling

Early expert airway management may be necessary because severe edema can make later intubation extremely difficult.

3. Oxygen

Administer high-flow oxygen when there is:

• Respiratory distress
• Hypoxemia
• Shock
• Severe anaphylaxis

4. IV Fluids

Anaphylaxis causes marked vasodilation and capillary leakage.

For hypotension:

• Give rapid isotonic crystalloid
• Repeat according to clinical response

5. Bronchospasm

Persistent wheezing after epinephrine can be treated with an inhaled beta-2 agonist such as albuterol/salbutamol.

Bronchodilators are adjuncts and must not replace epinephrine.

6. Antihistamines

Antihistamines may improve:

• Urticaria
• Pruritus

However:

Antihistamines do not treat airway obstruction or shock and must never delay epinephrine.

Local Reactions

For uncomplicated local pain and swelling:

• Cold compresses
• Elevation when appropriate
• Oral analgesics
• Oral antihistamines for itching

Large local reactions are inflammatory and do not routinely require antibiotics unless there is evidence of secondary infection.

Stinger Removal

Honey bees may leave a barbed stinger and venom sac behind.

Remove a retained stinger as rapidly as possible.

Scraping or flicking it out promptly is reasonable. The important principle is to minimize continued venom delivery rather than delaying removal.

Wasps, hornets, and yellow jackets generally do not leave their stingers behind and may sting repeatedly.

Massive Envenomation

Treatment focuses on:

• Airway and ventilation
• IV fluids
• Hemodynamic support
• Renal monitoring
• Electrolyte management
• Treatment of rhabdomyolysis
• Treatment of hemolysis
• Management of shock

Monitor:

• CK
• Creatinine
• Potassium
• Urine output
• Hemoglobin
• LDH/bilirubin when hemolysis is suspected

Severe acute kidney injury may require renal replacement therapy/dialysis.

Antidote

There is no specific antidote for Hymenoptera venom.

For anaphylaxis, however, epinephrine is the essential life-saving treatment.

Monitoring

Patients with systemic reactions should receive:

• Continuous pulse oximetry
• Cardiac monitoring
• Serial blood pressure measurements
• Repeated airway assessment

After massive envenomation, laboratory monitoring should continue because renal and muscle injury may evolve over 24–48 hours.

Admission

Hospital admission should be considered for:

• Cardiovascular instability
• Persistent airway or pulmonary symptoms
• Severe anaphylaxis
• Recurrent symptoms
• Massive numbers of stings
• Rhabdomyolysis
• Hemolysis
• Acute kidney injury
• Significant electrolyte abnormalities

Severe anaphylaxis or massive envenomation may require ICU care.

Follow-Up After Anaphylaxis

Patients with a systemic allergic reaction should be evaluated for:

• Prescription of an epinephrine autoinjector
• Education about its use
• Allergy/immunology referral
• Consideration of venom immunotherapy

Venom immunotherapy can markedly reduce the risk of recurrent systemic reactions in appropriately selected patients.

Prognosis

Most uncomplicated local reactions resolve without serious consequences.

Anaphylaxis

Can produce:

• Airway obstruction
• Shock
• Cardiac arrest
• Death within minutes

Delayed epinephrine increases the risk of severe outcomes.

Massive Envenomation

Systemic venom effects can cause:

• Rhabdomyolysis
• Hemolysis
• Acute kidney injury
• Myocardial injury
• Multiorgan failure

Prompt aggressive supportive care substantially improves outcome.

Important Pitfalls

1. Waiting for hypotension before giving epinephrine

Anaphylaxis should be treated promptly when significant airway, breathing, or circulatory involvement develops.

2. Giving antihistamines instead of epinephrine

Antihistamines treat skin symptoms but do not reverse life-threatening airway obstruction or shock.

3. Routine IV epinephrine bolus

Routine IV epinephrine boluses for anaphylaxis can cause serious cardiovascular complications.

IM epinephrine is first-line.

4. Assuming one sting cannot be dangerous

A single sting can cause fatal anaphylaxis in a sensitized patient.

5. Assuming multiple stings only cause allergy

Massive envenomation causes direct venom toxicity, including rhabdomyolysis, hemolysis, and renal failure.

6. Missing delayed renal injury

AKI following massive envenomation may become apparent over the next 24–48 hours.

High-Yield Toxicology Pearls

Bee sting toxicity has two major patterns: anaphylaxis and massive envenomation.

Think:

One sting + wheeze/stridor/hypotension → ANAPHYLAXIS

versus

Many stings + rhabdomyolysis/hemolysis/AKI → MASSIVE ENVENOMATION

Key points:

• A single sting can cause fatal anaphylaxis
• Anaphylaxis is IgE-mediated and not dose-dependent
• Massive envenomation is dose-dependent direct venom toxicity
• IM epinephrine is first-line for anaphylaxis
• Adult IM epinephrine dose: 0.5 mg
• Repeat IM epinephrine after about 5 minutes if significant symptoms persist
• Antihistamines are adjuncts only
• Remove retained honey-bee stingers promptly
• Multiple stings can cause rhabdomyolysis, hemolysis, and acute kidney injury
• Systemic toxic complications may worsen over 24–48 hours
• There is no specific venom antidote
• Patients with previous systemic allergic reactions should be considered for an epinephrine autoinjector and venom-allergy evaluation

Toxicology – Barium

Core concept

Barium is a heavy metal whose toxicity depends strongly on its chemical form.

The key distinction is:

Soluble barium salts = highly toxic

Barium sulfate = essentially insoluble and minimally absorbed

The hallmark of significant poisoning is:

Profound hypokalemia + muscle weakness/paralysis + cardiac dysrhythmias

Forms and Uses

Toxic soluble forms

Examples include:

• Barium carbonate
• Barium chloride
• Barium hydroxide

These compounds can be absorbed from the gastrointestinal tract and cause severe systemic toxicity.

Relatively nontoxic insoluble form

• Barium sulfate

Barium sulfate is used as a radiographic contrast material and is poorly absorbed from the gastrointestinal tract.

Toxic Dose

Toxicity depends on:

• Chemical form
• Solubility
• Dose
• Route of exposure

The cited source reports fatal poisoning after ingestion of approximately 1–15 g of soluble barium salts.

Pathophysiology

Barium interferes with potassium movement across cell membranes.

A useful simplified sequence is:

Barium blocks potassium channels → potassium shifts intracellularly → profound extracellular hypokalemia → impaired membrane depolarization → muscle weakness/paralysis

This explains many of the major toxic effects.

Barium can also:

• Stimulate acetylcholine release
• Increase smooth and skeletal muscle activity initially
• Affect cardiac conduction
• Stimulate insulin secretion
• Produce hypoglycemia

Major Toxic Effects

Think of barium poisoning as a combination of:

GI toxicity + profound hypokalemia + neuromuscular paralysis + cardiac dysrhythmias

Clinical Features

Gastrointestinal

Early symptoms commonly include:

• Nausea
• Vomiting
• Diarrhea
• Severe abdominal pain

Marked intestinal smooth-muscle stimulation can produce intense gastrointestinal symptoms.

Neuromuscular

Muscle abnormalities may progress from stimulation to paralysis.

Features include:

• Muscle twitching
• Cramps
• Myalgia
• Rigidity
• Weakness
• Hyporeflexia
• Flaccid paralysis

Severe weakness may involve respiratory muscles.

Neurologic

Possible findings include:

• Anxiety
• Giddiness
• Headache
• Vertigo
• Tinnitus
• Mydriasis
• Seizures

Severe toxicity may progress to CNS depression.

HEENT

Possible findings:

• Salivation
• Perioral paresthesia
• Muscle twitching
• Dysarthria
• Dysphagia

Cardiovascular

Cardiac toxicity is closely related to severe hypokalemia.

Possible abnormalities include:

• Hypertension
• Premature ventricular complexes
• QT abnormalities
• Ventricular tachycardia
• Ventricular fibrillation
• Asystole

Life-threatening dysrhythmias are a major cause of mortality.

Respiratory

Toxicity may cause:

• Respiratory muscle weakness
• Respiratory paralysis
• Respiratory failure

Inhalational exposure may also cause:

• Sore throat
• Cough
• Bronchial irritation
• Dyspnea
• Pulmonary edema

Renal

• Acute kidney injury may occur

Musculoskeletal

Severe poisoning can cause:

• Flaccid paralysis
• Rhabdomyolysis
• Myoclonus
• Muscle stiffness and cramps

Dermatologic

Direct contact may cause:

• Skin irritation
• Chemical burns, particularly with reactive forms

Metabolic

The most important metabolic abnormality is:

Profound hypokalemia

Other abnormalities may include:

• Hypophosphatemia
• Hypomagnesemia
• Metabolic acidosis
• Hypoglycemia

Characteristic Laboratory Finding

The classic biochemical clue is:

Severe, sometimes refractory hypokalemia

This can be profound and may require unusually large amounts of potassium replacement.

Diagnosis

Diagnosis is based on:

Exposure history + severe hypokalemia + GI symptoms + muscle weakness/paralysis ± cardiac dysrhythmias

Essential Investigations

In significant poisoning obtain frequent:

• Serum potassium
• Magnesium
• Calcium
• Phosphate
• Glucose
• Renal function
• Electrolytes

In severe poisoning, electrolytes may need to be checked hourly during active correction.

Cardiorespiratory Assessment

Consider:

• Continuous ECG monitoring
• 12-lead ECG
• Pulse oximetry
• Arterial or venous blood gas when clinically indicated

Additional Investigations

Depending on presentation:

• Urinalysis
• Creatine kinase
• Chest radiograph after significant inhalational exposure
• Abdominal imaging in selected ingestions

Blood or urine barium concentrations can confirm exposure but generally do not guide immediate emergency treatment.

Differential Diagnosis

The combination of:

GI symptoms + profound hypokalemia + paralysis + dysrhythmias

should prompt consideration of barium poisoning.

Other causes of severe hypokalemia and paralysis should also be considered, including:

• Hypokalemic periodic paralysis
• Gastrointestinal potassium losses
• Renal potassium wasting
• Diuretic toxicity
• Beta-agonist toxicity
• Insulin excess
• Other causes of intracellular potassium shift

Treatment

1. Stabilization

Management begins with:

• Airway assessment
• Oxygenation
• Ventilatory support
• Continuous cardiac monitoring
• IV access

Severe cases should be managed in a critical-care setting.

2. Potassium Replacement

Aggressive potassium replacement is the cornerstone of treatment.

Because the hypokalemia may be profound, unusually large replacement requirements can occur.

Important:

• Replace potassium carefully
• Monitor ECG continuously
• Recheck potassium frequently
• Also monitor magnesium, calcium, and phosphate

As barium toxicity resolves, potassium may shift back extracellularly, so rebound hyperkalemia is possible if replacement is excessive.

3. Respiratory Failure

If respiratory muscle paralysis develops:

• Endotracheal intubation
• Mechanical ventilation

may be required.

4. Dysrhythmias

Treat life-threatening dysrhythmias according to standard ACLS principles, while aggressively correcting the underlying electrolyte disturbance.

Correction of hypokalemia is essential.

5. Hypertension

Treat severe hypertension with standard short-acting IV antihypertensive therapy when clinically necessary.

Gastrointestinal Decontamination

Do not induce vomiting.

Activated charcoal is generally not useful for metals because it does not reliably adsorb them.

Older references describe administration of sulfate salts to convert soluble barium into poorly soluble barium sulfate within the gastrointestinal tract.

This strategy requires toxicology consultation because:

• Evidence is limited
• Electrolyte complications are possible
• Some older treatment approaches carry significant risk

Routine gastric lavage is not generally part of modern poisoning management except in very unusual circumstances.

Sulfate Therapy

The theoretical principle is:

Soluble barium + sulfate → insoluble barium sulfate → decreased absorption

Historically, oral sodium sulfate or magnesium sulfate has been used after ingestion.

However, intravenous sulfate is not routinely recommended, because systemic precipitation may cause renal injury and other complications.

Hemodialysis

Barium is potentially dialyzable.

Hemodialysis may be considered in severe poisoning, especially when there is:

• Severe persistent hypokalemia
• Life-threatening dysrhythmia
• Paralysis
• Renal failure
• Ongoing severe toxicity despite supportive care

Early toxicology and nephrology consultation is appropriate in severe cases.

Antidote

There is no specific antidote for barium poisoning.

Treatment is based on:

• Aggressive electrolyte correction
• Cardiorespiratory support
• Prevention of further absorption
• Extracorporeal removal in selected severe cases

Monitoring

Symptomatic patients require:

• Continuous cardiac monitoring
• Continuous respiratory monitoring
• Frequent neurologic assessment
• Serial potassium measurements
• Serial magnesium, calcium, and phosphate
• Serial glucose
• Renal function monitoring

Admission

Hospital admission is indicated when there is:

• Hypokalemia
• Significant muscle weakness
• Paralysis
• Dysrhythmia
• Respiratory symptoms
• Acute kidney injury
• Persistent gastrointestinal symptoms

Severe poisoning generally requires ICU management.

Prognosis

With prompt treatment, many patients recover.

Symptoms often improve substantially within approximately 24 hours, although:

• Weakness
• Paralysis
• Neuromuscular dysfunction

may persist for several days or longer after severe exposure.

Untreated severe poisoning can be fatal.

Important Pitfalls

1. Underestimating hypokalemia

The potassium deficit can be profound and may require aggressive replacement.

2. Failing to monitor electrolytes frequently

Rapid changes in potassium can occur during treatment.

3. Missing respiratory paralysis

Progressive weakness can involve respiratory muscles and cause sudden respiratory failure.

4. Missing dysrhythmias

Severe hypokalemia can cause fatal ventricular arrhythmias.

5. Confusing barium sulfate with toxic soluble barium

Barium sulfate used for radiologic contrast is poorly absorbed and is fundamentally different from soluble barium salts.

High-Yield Toxicology Pearls

Barium poisoning = profound hypokalemia + paralysis + dysrhythmias

Think:

GI symptoms + severe hypokalemia + muscle weakness + ventricular arrhythmias

Key points:

• Soluble barium salts are highly toxic
• Barium sulfate is poorly absorbed
• Main mechanism: potassium channel interference
• Hallmark laboratory abnormality: profound hypokalemia
• Neuromuscular toxicity may progress to flaccid paralysis
• Respiratory muscle paralysis may require ventilation
• Cardiac toxicity includes VT, VF, and asystole
• Treatment centers on aggressive potassium replacement and supportive care
• No specific antidote
• Hemodialysis may be considered in severe poisoning
• Frequent potassium and ECG monitoring are essential

Toxicology – Barbiturates

Core concept

Barbiturates are CNS depressants used mainly for seizure control, anesthesia, and sedation.

In overdose, the dominant toxicity is:

Progressive CNS depression → respiratory depression/apnea → hypotension → coma

Death is usually related to complications such as:

• Aspiration
• Respiratory failure
• Hypoxia
• Prolonged hypotension
• Pressure injury/rhabdomyolysis

Examples

Ultra-short acting

• Methohexital
• Thiopental
• Thiamylal

Short-acting

• Butabarbital
• Pentobarbital
• Secobarbital
• Hexobarbital

Long-acting

• Phenobarbital
• Mephobarbital
• Metharbital
• Primidone

Primidone is metabolized partly to phenobarbital and can therefore produce a similar toxic syndrome.

Pathophysiology

Barbiturates enhance GABA-mediated inhibitory neurotransmission in the CNS.

They bind to the GABA-A receptor complex and enhance chloride channel activity, producing:

Neuronal inhibition → sedation → coma → respiratory depression

Unlike benzodiazepines, severe barbiturate overdose can cause profound respiratory and cardiovascular depression.

Toxic Dose

There is no single universally toxic dose.

Important factors include:

• Specific barbiturate
• Acute versus chronic use
• Development of tolerance
• Coingestants
• Age
• Comorbid disease

In a barbiturate-naive patient, toxicity may occur not far above the therapeutic range, while chronic users may tolerate much larger doses.

Risk Factors

Greater toxicity may occur with:

• Advanced age
• Coingestion of other CNS depressants
• Alcohol
• Opioids
• Benzodiazepines
• Renal or hepatic dysfunction, depending on the agent

Drug interactions may alter phenobarbital concentrations.

Clinical Features

Neurologic

The major manifestation is dose-dependent CNS depression.

Early findings:

• Somnolence
• Ataxia
• Nystagmus
• Dysarthria
• Hyporeflexia

Progressive toxicity:

• Stupor
• Coma
• Loss of protective airway reflexes

Respiratory

• Hypoventilation
• Respiratory depression
• Apnea
• Aspiration risk

Respiratory depression is a major cause of morbidity and mortality.

Cardiovascular

• Hypotension
• Bradycardia may occur
• Cardiovascular collapse in severe poisoning

Hypotension may be especially prominent with rapid IV administration.

Temperature

Hypothermia is common in severe intoxication.

Dermatologic

Characteristic pressure-related bullae may develop during prolonged coma.

These are sometimes referred to as coma bullae.

Musculoskeletal

Prolonged immobilization can cause:

• Rhabdomyolysis
• Pressure necrosis
• Compartment syndrome

Gastrointestinal / Hepatic

Rare complications include:

• Hepatic injury
• Aspiration-related complications

Metabolic

• Hypoglycemia has occasionally been reported

Diagnosis

Diagnosis is based on:

Exposure history + typical sedative toxidrome + exclusion of other causes of coma

Laboratory Evaluation

Phenobarbital concentration

A serum phenobarbital level is useful when:

• Phenobarbital ingestion is suspected
• Primidone ingestion is suspected
• Severe or prolonged toxicity is present

Serial levels can help assess whether concentrations are rising or falling.

Additional investigations

In significant poisoning consider:

• Pulse oximetry
• Blood gas if respiratory depression is present
• Serum electrolytes
• BUN
• Creatinine
• Glucose
• Creatine kinase
• ECG

In intentional overdose also consider:

• Acetaminophen level
• Salicylate level
• Evaluation for other coingestants

If the cause of altered mental status is uncertain, investigate alternative neurologic, infectious, metabolic, and toxicologic causes.

Differential Diagnosis

Toxicologic causes

• Benzodiazepines
• Opioids
• Ethanol
• Valproate
• Carbamazepine
• Other sedative-hypnotics

Non-toxicologic causes

• Hypoglycemia
• Hypothermia
• Intracranial hemorrhage
• CNS infection
• Electrolyte disturbances
• Hypoxia

Treatment

1. Airway

Early airway protection is the priority.

Consider endotracheal intubation if the patient has:

• Severe CNS depression
• Loss of airway reflexes
• Hypoventilation
• Apnea
• Recurrent aspiration

2. Breathing

Provide:

• Supplemental oxygen
• Assisted ventilation when required
• Mechanical ventilation for respiratory failure

3. Circulation

Treat hypotension initially with:

• IV isotonic crystalloid

If hypotension persists despite adequate fluids:

• Use vasopressors according to standard critical-care practice

Gastrointestinal Decontamination

Activated charcoal

A single dose of activated charcoal may be considered after a substantial recent ingestion when:

• Presentation is early
• The airway is intact or protected
• Aspiration risk is acceptable

Gastric lavage

Although older references recommended gastric lavage for severe early presentations, routine gastric lavage is not generally recommended in contemporary poisoning management because potential harms usually outweigh benefit.

It is reserved for exceptional circumstances.

Multiple-Dose Activated Charcoal

Multiple-dose activated charcoal (MDAC) can enhance elimination of phenobarbital.

It may be considered in significant phenobarbital poisoning, particularly when:

• Toxicity is severe
• Serum levels remain high
• Gastrointestinal function is intact
• The airway is protected

MDAC is not useful for all barbiturates.

Avoid or discontinue it in:

• Ileus
• Gastrointestinal obstruction
• Unprotected airway
• Significant aspiration risk

Urinary Alkalinization

Phenobarbital is a weak acid, and urinary alkalinization can increase renal elimination.

However:

Urinary alkalinization is not routinely recommended as the primary enhanced-elimination strategy in modern phenobarbital poisoning, because clinical benefit is limited and MDAC or extracorporeal treatment may be more useful in severe cases.

If used, careful monitoring is required for:

• Potassium
• Sodium
• Fluid balance
• Acid-base status

Extracorporeal Treatment

Hemodialysis can substantially increase phenobarbital elimination and may be considered in severe long-acting barbiturate poisoning.

Potential indications include:

• Prolonged deep coma
• Severe respiratory depression requiring prolonged ventilation
• Persistent hypotension
• Severe toxicity with very high or rising concentrations
• Significant renal impairment
• Clinical deterioration despite supportive care

Modern high-efficiency hemodialysis is generally preferred over charcoal hemoperfusion when extracorporeal treatment is needed.

Antidote

There is no specific antidote for barbiturate poisoning.

Management is primarily:

Airway + ventilation + cardiovascular support + enhanced elimination when appropriate

Monitoring

Significantly poisoned patients should receive:

• Continuous cardiac monitoring
• Continuous oxygen saturation monitoring
• Serial neurologic assessment
• Serial blood pressure monitoring
• Temperature monitoring

Also monitor for:

• Aspiration
• Pressure injury
• Rhabdomyolysis
• Compartment syndrome
• Renal dysfunction

Admission

Hospital admission is appropriate when there is:

• Persistent sedation
• Ataxia preventing safe ambulation
• Respiratory depression
• Hypotension
• Coma
• Significant phenobarbital toxicity
• Rising drug concentrations
• Serious coingestion

Severely poisoned patients generally require ICU management.

Prognosis

Large overdoses may cause prolonged coma lasting several days, particularly with long-acting agents such as phenobarbital.

Most patients recover with good supportive care unless complications develop.

Important complications include:

• Hypoxic brain injury
• Aspiration pneumonia
• Rhabdomyolysis
• Pressure necrosis
• Compartment syndrome
• Prolonged hypotension

Important Pitfalls

1. Failure to protect the airway

Profound CNS depression can rapidly cause:

• Aspiration
• Hypoxia
• Respiratory arrest

2. Assuming all coma is due to the barbiturate

Other causes of altered mental status must still be considered.

3. Missing pressure-related complications

Prolonged coma can cause:

• Coma bullae
• Rhabdomyolysis
• Compartment syndrome

4. Missing coingestants

Severe or fatal poisoning commonly involves additional CNS depressants.

High-Yield Toxicology Pearls

Barbiturate overdose = coma + respiratory depression + hypotension + hypothermia

Think:

Sedative toxidrome + nystagmus/hyporeflexia + apnea + hypotension

Key points:

• Mechanism: enhancement of GABA-A activity
• Major toxicity: CNS and respiratory depression
• Severe overdose may cause coma and apnea
• Hypothermia and hypotension are common
• Pressure-related bullae and rhabdomyolysis may occur
• No specific antidote
• Main treatment: aggressive supportive care
• Phenobarbital levels are useful when phenobarbital or primidone is involved
• Multiple-dose activated charcoal may enhance phenobarbital elimination
• Hemodialysis may be useful in severe phenobarbital poisoning
• Early airway management is critical to prevent aspiration and hypoxic injury

Toxicology – Baclofen

Core concept

Baclofen is a centrally acting GABA-B receptor agonist used to treat spasticity.

In overdose, the dominant toxic effect is:

CNS depression → respiratory depression → coma

Severe poisoning can mimic catastrophic neurologic injury because patients may develop profound coma, flaccidity, hyporeflexia, and abnormal brainstem reflexes.

Forms and Uses

Baclofen is available as:

• Oral tablets
• Intrathecal preparations delivered by pump

It is used for spasticity associated with:

• Multiple sclerosis
• Cerebral palsy
• Spinal cord injury
• Other spinal cord disorders

Toxic Dose

Large oral overdoses can cause severe toxicity.

The cited source reports:

• 300–1,000 mg orally may cause significant toxicity
• Doses above approximately 1.5 g may be fatal

However, toxicity depends strongly on:

• Renal function
• Age
• Coingestants
• Chronic baclofen use

Patients with renal impairment can develop toxicity at therapeutic doses because baclofen is predominantly renally eliminated.

Pathophysiology

Baclofen stimulates GABA-B receptors, reducing excitatory neurotransmission and decreasing spinal motor neuron activity.

In overdose:

Excess GABA-B activity → profound CNS depression + respiratory depression + autonomic/cardiovascular effects

Risk Factors

Toxicity is more likely or more severe with:

• Renal insufficiency
• Advanced age
• Large ingestion
• Other CNS depressants
• Intrathecal pump malfunction or dosing error

Coingestion with sedatives can markedly worsen CNS and respiratory depression.

Clinical Features

Neurologic

The major manifestation is CNS depression.

Clinical progression may include:

• Confusion
• Agitation
• Hallucinations
• Somnolence
• Coma
• Hyporeflexia
• Flaccidity
• Abnormal brainstem reflexes

Severe overdose may resemble:

• Brain death
• Structural brainstem injury

Other neurologic features include:

• Myoclonus
• Seizures
• Tremor
• Dystonia
• Chorea

Vital Signs

Common findings include:

• Bradycardia
• Hypothermia
• Hypotension
• Respiratory depression

Tachycardia may occur during recovery.

Cardiovascular

Possible complications:

• Bradycardia
• Hypotension
• AV block
• Premature ventricular complexes
• Atrial fibrillation
• Other dysrhythmias

Respiratory

Respiratory depression is common in severe poisoning and may require mechanical ventilation.

Gastrointestinal

• Nausea
• Vomiting

Renal / Urinary

• Urinary retention
• Urinary incontinence

Musculoskeletal

Rhabdomyolysis may develop after:

• Prolonged coma
• Prolonged immobilization
• Seizures

Dermatologic

Pressure-related bullae may occur after prolonged coma.

Baclofen Withdrawal

Abrupt discontinuation after chronic use can produce a potentially severe withdrawal syndrome.

Features include:

• Agitation
• Hallucinations
• Delirium
• Paranoia
• Seizures
• Autonomic instability

Intrathecal baclofen withdrawal can be particularly severe and potentially life-threatening.

The key treatment is generally:

Restore baclofen + supportive care + benzodiazepines when required

Baclofen should subsequently be tapered appropriately rather than abruptly discontinued.

Diagnosis

Diagnosis is usually clinical:

Exposure history + CNS depression ± bradycardia, hypotension, respiratory depression, or seizures

Essential investigations

Minimally symptomatic patients may require few investigations.

In significant poisoning consider:

• ECG
• Pulse oximetry
• Blood gas when respiratory depression is present
• Electrolytes
• BUN
• Creatinine
• Creatine kinase

Renal function is particularly important because impaired baclofen clearance substantially increases toxicity.

Overdose screening

In intentional overdose, consider:

• Acetaminophen concentration
• Salicylate concentration
• Evaluation for other coingestants

If altered mental status is unexplained or does not fit the toxicologic picture, consider other investigations such as neuroimaging or infectious workup.

Baclofen levels

Serum baclofen concentrations are generally not useful for acute clinical management.

Differential Diagnosis

Other causes of CNS depression include:

Toxicologic

• Ethanol
• Benzodiazepines
• Opioids
• Barbiturates
• Sedative-hypnotics
• Other CNS depressants

Non-toxicologic

• CNS infection
• Intracranial hemorrhage
• Intracranial mass
• Seizure/postictal state
• Metabolic disturbance
• Severe electrolyte abnormality

Treatment

1. Airway and Breathing

Airway management is the highest priority.

Provide:

• Supplemental oxygen
• Assisted ventilation when required
• Endotracheal intubation for severe CNS or respiratory depression

Many severely poisoned patients require mechanical ventilation until the baclofen effect resolves.

2. Circulation

For hypotension:

• IV isotonic fluids
• Vasopressors if hypotension persists

Current vasopressor selection should follow standard critical-care practice.

3. Seizures

Treat seizures with benzodiazepines.

If seizures persist:

• Escalate anticonvulsant therapy according to standard status epilepticus management
• Ensure adequate oxygenation and ventilation

4. Rhabdomyolysis

Monitor:

• CK
• Renal function
• Potassium
• Urine output

Treat according to severity and associated complications.

Gastrointestinal Decontamination

Do not induce vomiting, because CNS depression may develop rapidly and aspiration risk is significant.

Activated charcoal may be considered after a substantial recent ingestion when:

• Presentation is early
• The airway is intact or protected
• Aspiration risk is acceptable

Routine gastric lavage is not generally part of contemporary poisoning management and would only be considered in exceptional circumstances.

Intrathecal Baclofen Overdose

Intrathecal overdose can result from:

• Pump malfunction
• Programming error
• Incorrect drug concentration
• Accidental excessive administration

Management includes:

• Immediate supportive care
• Airway and ventilatory support
• Urgent consultation with toxicology and specialists familiar with intrathecal pumps

In severe cases, specialist-directed removal of baclofen-containing CSF has historically been described.

Hemodialysis

Because baclofen is predominantly renally cleared and has favorable dialyzability, hemodialysis can be clinically important in severe toxicity, especially in patients with renal impairment.

It may be considered when there is:

• Severe/prolonged coma
• Respiratory failure
• Significant renal dysfunction
• Failure to improve with supportive care

Antidote

There is no specific antidote for baclofen poisoning.

Physostigmine

Routine use is not recommended.

Serious adverse effects, including cardiac arrest, have been reported.

Flumazenil

Routine use is also not recommended.

It has inconsistent benefit and may provoke seizures, particularly in mixed overdoses.

Monitoring

Patients with significant toxicity should receive:

• Continuous cardiac monitoring
• Continuous respiratory monitoring
• Serial neurologic examinations
• Renal function monitoring
• CK monitoring when prolonged coma or seizures occur

Admission

Hospital admission is indicated for:

• CNS depression
• Respiratory depression
• Seizures
• Hypotension
• Dysrhythmias
• Significant renal impairment
• Intrathecal overdose

Patients requiring ventilatory or cardiovascular support generally need ICU care.

Prognosis

Profound coma can persist for several days, especially after massive overdose or in renal impairment.

Despite dramatic neurologic findings, many patients recover completely with supportive care.

Poor outcomes are generally related to complications such as:

• Prolonged hypoxia
• Severe hypotension
• Aspiration
• Rhabdomyolysis
• Seizure-related injury

Important Pitfalls

1. Mistaking severe toxicity for brain death

Massive baclofen overdose can produce:

• Deep coma
• Flaccidity
• Absent or impaired reflexes
• Abnormal brainstem reflexes

Therefore, profound neurologic suppression should not automatically be interpreted as irreversible neurologic injury.

2. Missing renal impairment

Renal failure dramatically prolongs baclofen toxicity.

Even therapeutic dosing can cause severe poisoning when renal clearance is impaired.

3. Abruptly stopping chronic baclofen

Sudden withdrawal may cause:

• Severe agitation
• Hallucinations
• Delirium
• Seizures
• Autonomic instability

4. Missing coingestants

Intentional overdose frequently requires evaluation for additional substances.

High-Yield Toxicology Pearls

Baclofen overdose = CNS depression + respiratory depression + bradycardia ± seizures

Think:

Coma + flaccidity/hyporeflexia + bradycardia + respiratory depression

Key points:

• Mechanism: GABA-B receptor agonism
• Major toxicity: profound CNS depression
• Severe cases may mimic brain death
• Respiratory depression may require prolonged mechanical ventilation
• Renal impairment greatly increases toxicity
• Serum baclofen levels are usually not clinically useful
• No specific antidote
• Treatment is primarily supportive care
• Hemodialysis may be useful in severe toxicity, particularly with renal impairment
• Abrupt withdrawal can cause agitation, hallucinations, delirium, and seizures

Toxicology – Asphyxiant Gases

Core concept

Simple asphyxiant gases cause toxicity by displacing oxygen from the surrounding atmosphere, resulting in alveolar hypoxia → systemic hypoxemia → tissue hypoxia.

They do not usually exert a specific cellular toxic effect. Their danger comes primarily from reducing the amount of oxygen available for breathing.

Examples include:

• Acetylene
• Argon
• Butane
• Carbon dioxide
• Helium
• Hydrogen
• Methane
• Natural gas
• Neon
• Nitrogen
• Propane
• Other inert gases

Carbon monoxide and pulmonary irritant gases are separate toxicologic entities.

Pathophysiology

A simple asphyxiant:

Displaces atmospheric O₂ → lowers inspired O₂ → alveolar hypoxia → hypoxemia → tissue hypoxia

Clinical effects generally become apparent when ambient oxygen falls below approximately 15% and become severe below approximately 10%.

Some liquefied or rapidly expanding gases can also cause cold injury/frostbite after direct tissue contact.

Risk Factors

Risk is increased by:

• Poorly ventilated or confined spaces
• Intentional inhalational abuse
• Significant underlying cardiac or pulmonary disease
• Advanced age
• High altitude

Patients with cardiopulmonary disease may become symptomatic with relatively small reductions in ambient oxygen.

Pregnancy

Severe maternal hypoxia can cause:

• Fetal hypoxia
• Fetal distress

Clinical Features

Symptoms correlate directly with the severity and duration of hypoxia.

Early hypoxia

• Headache
• Agitation
• Air hunger
• Tachypnea
• Hyperpnea
• Tachycardia
• Diaphoresis

Progressive hypoxia

• Cyanosis
• Lethargy
• Confusion
• Myocardial ischemia
• Dysrhythmias

Severe / preterminal hypoxia

• Respiratory depression
• Hypotension
• Bradycardia
• Mydriasis
• Coma
• Ventricular dysrhythmias
• Idioventricular rhythm
• Asystole

Diagnosis

Diagnosis is based on:

Exposure history + evidence of hypoxia + improvement after removal from exposure and oxygen

Essential investigations

• Pulse oximetry
• Arterial blood gas when clinically indicated

If another toxic exposure is possible, obtain:

• Carboxyhemoglobin level
• Methemoglobin level

Important limitation

Standard pulse oximetry may be misleading in carbon monoxide poisoning, so concurrent CO exposure must be considered in appropriate settings.

Additional investigations

Depending on clinical circumstances:

• Serum electrolytes
• BUN
• Creatinine
• Blood glucose
• ECG

In suspected overdose or unexplained altered consciousness:

• Acetaminophen level
• Salicylate level

If altered mental status persists despite adequate oxygenation, investigate alternative causes as indicated, including:

• CT brain
• Lumbar puncture
• Blood cultures
• CSF studies

Differential Diagnosis

Other causes of hypoxia or altered mental status should be considered.

Toxicologic causes

• Carbon monoxide
• Cyanide
• Hydrogen sulfide
• Methemoglobinemia

Non-toxicologic causes

• Pulmonary embolism
• Primary pulmonary disease
• Hemoglobin disorders
• Cardiovascular disease
• Other neurologic or metabolic causes of altered consciousness

Treatment

1. Remove from exposure

The patient should be immediately removed from the contaminated environment.

Rescuer safety is essential, especially in confined spaces, because rescuers can also become hypoxic.

2. Oxygen

Administer high-flow 100% oxygen.

This is the principal treatment for simple asphyxiant exposure.

3. Airway and ventilation

Provide:

• Airway support
• Assisted ventilation
• Endotracheal intubation when necessary

4. Supportive care

Monitor and treat:

• Hypotension
• Dysrhythmias
• Myocardial ischemia
• Electrolyte abnormalities
• Neurologic complications

5. Persistent altered mental status

If the patient does not rapidly improve with oxygen, evaluate for alternative or concurrent causes.

Appropriate empiric measures may include:

• Blood glucose measurement
• Dextrose if hypoglycemic
• Naloxone when opioid toxicity is possible
• Thiamine in appropriate clinical circumstances

6. Seizures

Seizures may occur because of severe hypoxia.

If they persist despite correction of oxygenation:

• Treat with benzodiazepines as first-line anticonvulsant therapy

Antidote

There is no specific antidote for simple asphyxiant gases.

The key therapy is:

Removal from exposure + 100% oxygen + airway/supportive care

Decontamination

Prehospital

• Remove from exposure
• Begin oxygen immediately

Hospital

Usually no specific decontamination is required unless another substance is also involved.

Direct contact with liquefied gases should prompt evaluation and treatment for frostbite/cold injury.

Monitoring

Symptomatic patients should receive:

• Continuous pulse oximetry
• Cardiac monitoring
• Serial neurologic assessment

Additional monitoring depends on the severity of hypoxia and suspected complications.

Admission

Hospital admission is appropriate for patients with:

• Persistent symptoms
• Persistent hypoxia despite oxygen
• Significant neurologic abnormalities
• Cardiac ischemia or dysrhythmias
• Other complications of hypoxia
• Suspected additional toxic exposure

Disposition

Patients who remain asymptomatic after removal from exposure and have no evidence of another toxic exposure may be observed for approximately 2–4 hours.

Discharge may be considered when:

• Symptoms have completely resolved
• Oxygenation is normal
• No complications of hypoxia are present
• No significant concurrent toxic exposure is suspected

Psychiatric assessment may be appropriate when exposure was intentional.

Prognosis

Prognosis depends primarily on:

Severity of hypoxia + duration of hypoxia

Prompt removal from exposure usually results in a good outcome.

Prolonged severe hypoxia can cause:

• Myocardial ischemia
• Dysrhythmias
• Anoxic brain injury
• Multiorgan injury
• Death

Important Pitfalls

1. Missing concurrent poisoning

Do not assume all hypoxia in a confined-space exposure is due to simple oxygen displacement.

Consider:

• Carbon monoxide
• Hydrogen sulfide
• Cyanide
• Pulmonary irritants

2. Rescuer injury

Entering an oxygen-deficient confined space without appropriate respiratory protection can result in multiple casualties.

3. Cold injury

Liquefied or rapidly expanding gases can cause frostbite.

4. Delayed recognition of hypoxic injury

Even after oxygenation is restored, complications such as myocardial injury or hypoxic brain injury may persist.

High-Yield Toxicology Pearls

Simple asphyxiants kill by oxygen displacement.

Think:

Confined space + low oxygen environment + neurologic/cardiopulmonary symptoms + rapid improvement with oxygen

Key points:

• Mechanism: decreased inspired oxygen
• Main toxicity: systemic tissue hypoxia
• Severe toxicity usually occurs when ambient O₂ is <10%
• Early findings: tachypnea, tachycardia, headache, agitation
• Late findings: respiratory depression, bradycardia, hypotension, coma, asystole
• Main treatment: remove from exposure + 100% oxygen
• No specific antidote
• Always consider CO, cyanide, H₂S, and methemoglobinemia
• Protect rescuers from oxygen-deficient environments
• Prognosis depends on the depth and duration of hypoxia